Great this has finally happened. The market reaction was pretty weak to the news so looks like the SP will be results driven in future. Although ramp up in the US will take time l'm looking forward to their next quarterly figures.
l've noticed many analysts in the US have downgraded their forecasts for the company on the basis of the product labeling alerting potential recipients of the possibility of stroke. From presentations l've listened to it appears that the issue is now less of a concern due to a better understanding of the cause and steps now taken to alleviate this problem.
l still believe this company will be an excellent performer for many years to come.
HIN Price at posting:
$2.17 Sentiment: LT Buy Disclosure: Held
